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Abstract Fraction sp3 (Fsp3) values were used to com-
pare the flatness of known scaffolds (used as privileged
structures, drug scaffolds, and in scaffold-hopping
approaches) and natural product (NP) scaffolds. The vast
majority of the known synthetic scaffolds are planar with
Fsp3 values\0.45 while the NP scaffold set is composed of
mainly non-flat scaffolds. The identification of new or
novel scaffolds to provide libraries of small diverse bio-
active compounds is of the utmost importance to chemical
biology and medicinal chemistry research. Non-flat scaf-
folds embedded in NPs may explore neglected areas of
chemical space. We performed a scaffold abstraction from
the dictionary of natural products (DNP), which resulted in
15,822 scaffolds. From this scaffold set, the vast majority
(70 %), are non-flat scaffolds with Fsp3 value[0.45. These
non-flat scaffolds may cover 83 % of ring systems that are
absent from screening set.
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Introduction
‘‘Chemical space’’ is vast, even the subset of the chemical
universe that is of interest to drug development of molec-
ular weight (MW)\500 Da is estimated to number *1060
[17]. This number is out of the practical range for synthetic
accessibility and not surprisingly, chemists have covered
only a tiny portion of this space. According to SciFinder
*107 chemical structures have been reported, to date.
Bioactive molecules generally exert their effect through
interaction with proteins so that biological space is sig-
nificantly more limited. Proteins are limited in their com-
binations of 20 different of amino acids, and the human
genome for instance, encodes only 20,000–25,000 protein-
coding genes (Consortium IHGS [11]). Binding molecules
are recognized by the protein in specific binding pockets,
complementary in shape and physicochemical properties to
the accommodated small molecule [57]. Biologically rel-
evant chemical space (BRCS) is just a tiny fraction of the
complete chemical space [13]. It is worthwhile mentioning
that ‘‘drug space’’ is even smaller than BRCS, such that not
every bioactive molecule presented in BRCS can be con-
sidered as a drug molecule. Drug space contains those
bioactive molecules that have favorable potency, selectiv-
ity, and pharmacokinetic properties (absorption, distribu-
tion, metabolism, and excretion) for use as a drug [32].
To cover the expanse of BRCS, it is necessary to avoid
strategies that generate structurally similar compounds
with similar biological profiles. However, current approa-
ches suffer from insufficient overlap of compounds (usu-
ally from synthetic libraries) and biological structure space
[58]. Optimization of the processes of producing new
chemical entities to help match chemical and biological
space is of great significance to modern drug discovery.
Several approaches, such as libraries of privileged scaf-
folds, scaffold-hopping, diversity-oriented synthesis
(DOS), and biology-oriented synthesis (BIOS) have been
introduced to address the issue.
Molecular scaffolds (core structures) play a fundamental
role in the navigation of ‘‘biologically relevant chemical
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space’’ and drug development. Identification of new scaf-
folds that have potential to provide libraries of small
diverse bioactive compounds is of utmost interest to
chemical biology and medicinal chemistry research. Sev-
eral studies have been directed toward the assessment of
scaffold diversity of drug data sets [4, 20, 55], screening
libraries [24, 29, 50], organic compounds databases [34,
59], and natural product (NP) databases [20, 24, 27]. These
studies show that scaffold space is vast and diverse while
bioactive and drug-like compounds only represent a small
fraction of principally available scaffold space [30], sug-
gesting that scaffold selection is important.
Natural products and their analogs have had high impact
as drugs because of the embedded biosynthetic molecular
recognition that transfers to therapeutic targets as described
by protein fold topology (PFT) [26, 38]. Computational
analysis revealed that NPs exhibit a remarkable structural
diversity of molecular frameworks and scaffolds. They
possess desirable drug-like properties rendering them ideal
starting points for the design of focused libraries [20].
Approximately 40 % of the chemical scaffolds displayed in
NPs are absent from synthetic compounds [31]. Further-
more, according to Hert et al. [24] 83 % of the ring scaf-
folds among the NPs are unrepresented among commercial
molecules. More complex molecules have the capacity to
access greater chemical space and results in greater
potential for compounds to complement the spatial sub-
tleties of target proteins [36].
We performed a statistical analysis on the known scaf-
folds presented in three different reviews, i.e., scaffold-
hopping, privileged scaffolds, and drug-building blocks
[54–56] to determine the proportion of the scaffolds that
were planar. The ‘‘Carbon bond saturation’’ defined by
fraction sp3 value (Fsp3) was used to classify flat and non-
flat scaffolds [36]. We undertook a scaffold abstraction
from the dictionary of natural products (DNP) to determine
the proportion of flat scaffolds (Fsp3 B0.45) versus non-flat
scaffolds (Fsp3 [0.45). Non-flat scaffolds have a potential
to introduce new anchor points to explore additional areas
of ‘‘biologically relevant chemical space’’. Increased out-
of-plane substituents may translate to increased selectivity
in interactions with proteins. The analysis shows that NP
scaffolds have a higher proportion of non-flat members
compared to set composed of scaffold-hopping, privileged
scaffolds, and drug-building blocks.
Two Sources of Chemical Space
Current chemical space includes compounds isolated from
nature, and those synthesized by different strategies.
Although NPs interrogate a different and larger area of
chemical space than synthetic compounds [18, 48], drugs
derived from both spaces show similar values for Lipinski
parameters. Lipinski’s ‘‘rule of five’’ (Ro5) has been pro-
posed to evaluate the drug-likeness of a chemical com-
pound, based on the physico-chemical properties [33].
About 80 % of NPs have less than two violations of the Ro5
[45]. Overall, NPs are more similar to drugs than com-
pounds obtained from combinatorial synthesis [16]. Drug
molecules are generally developed from less complex lead
compounds, so that lead compounds usually have a smaller
number of rings, fewer rotatable bonds, and smaller MW
and are more hydrophilic than the final drug molecule [21].
NPs as a Source of Drug Leads
Historically, NPs have proven to be one of the richest
sources of active ingredients of medicines. They are bio-
synthesized by enzymes within organism as primary or
secondary metabolites. Unlike primary metabolites, the
absence of secondary metabolites does not result in
immediate death, but the molecules may play an important
role in organism survival. Some NPs have been evolu-
tionary preselected to modulate biochemical pathways as
toxins, pheromones, attractants, and repellents. The medi-
cal outcomes far exceed the conversion of these natural
systems into drugs and, for example, in the area of cancer,
of the 175 small molecules therapeutics developed between
1940s and 2010, 48.6 % are NPs or directly derived thereof
(Newman and Cragg [41]).
High-quality libraries for high throughput screening
(HTS) are of the utmost importance to modern drug dis-
covery. Some technical drawbacks associated with NPs
render these molecules unfavorable for HTS [28]. The
major problems include the problem of the inherent slow-
ness of working with NP extracts using bioassay-guided
isolation [23]. Therefore, traditional iterative NP extraction
and isolation methodology cannot be easily integrated into
modern drug development programs. Several methods and
strategies have been developed to promote the speed and
efficiency of the NP discovery process. The introduction of
fractionation and advances in structure elucidation has been
a great step forward in fulfilling this goal [7–9, 22, 51, 62].
Combinatorial Chemistry as a Solution
For more than a decade, a super rapid method of synthesis,
combinatorial chemistry, promised to help solve the pro-
ductivity issue for HTS that would lead to a wealth of new
drugs. As a result, pharmaceutical companies started to
invest in making large libraries based on this strategy,
which resulted in a significant decline in attention toward
NPs. The focus of combinatorial chemistry was on quan-
tity, with insufficient attention given to quality. Although
combinatorial chemistry techniques proved to be success-
ful in the optimization of structures of many recently
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approved drugs, the number of new drugs has not increased
significantly [12, 14, 52].
Two Alternative Approaches
Two main approaches, diversity-oriented synthesis (DOS)
and libraries of ‘‘privileged structures’’ have emerged to
address the inherent combinatorial chemistry’s shortfalls
[40]. Lessons learned from NPs are beginning to impact on
synthetic strategies.
Diversity-Oriented Synthesis
DOS aims to maximize the number of structures and scaf-
folds produced from a given synthetic scheme to find the
most efficient ways to populate the largest amount of
chemical space. In order to achieve the highest levels of
structural diversity: (i) the building blocks, (ii) the stereo-
chemistry, (iii) the functional groups and, most importantly,
and (iv) the molecular framework must be varied [5]. A wide
variety of libraries has been made based on this approach
[39, 44, 53]. Recently, a new concept of DOS, so-called
biology-oriented synthesis (BIOS) has developed [27]. In
BIOS, NP scaffolds are employed as a core and diversity is
created around it. Several libraries have been generated
using this strategy resulting in discovery of protein phos-
phatase inhibitor [42], protein tyrosine phosphatase inhibitor
[43], estrogen receptor a/b (ERa/b) inhibitor, and 5-LOX
inhibitors [60]. A ‘‘parent–child scaffolds’’ concept was
derived from a ‘‘structural classification of natural products
(SCONP)’’ tree [6]. In fact, combining the results of SCONP
with the structural classification of proteins ‘‘PSSC’’ was a
great step toward the developing concept of BIOS.
Libraries of Privileged Scaffolds
Another important strategy to guide synthetic design and to
help enrich compound collections in biological activities is
that of privileged structures. The concept of privileged
structures was first proposed in relation to benzodiazepines
that bind to multiple, unrelated classes of proteins as high
affinity ligands (Fig. 1) [15].
Research over the next three decades has revealed more
privileged structures [46]. Recently, a comprehensive list
of privileged structures has been assembled [56]. Accord-
ing to the IUPAC definition, a privileged structure is a
substructure ‘‘that often consists of a semi-rigid scaffold,
which is able to present multiple, hydrophobic residues
without undergoing hydrophobic collapse.’’ In this way, the
core preserves most of the binding potential when the
compound is exposed to an aqueous medium [3]. The
evolving role of NPs in drug discovery to provide effective
drugs supports the idea that NPs can be viewed as a pop-
ulation of privileged structures selected by evolutionary
pressures to interact with a wide variety of proteins [26,
28]. NP-like libraries based on privileged scaffolds attempt
to rapidly generate large collections of compounds that
possess greater diversity and incorporate optimized physi-
cal and pharmacological properties into their structures.
Interestingly, these libraries also provide a useful tool in
the identification of new targets [1, 49].
How Diverse are the Known Scaffolds?
Molecular scaffolds play an important role in providing the
tools to interrogate BRCS and in drug development. The
identification of new scaffolds is of utmost importance to
chemical biology and medicinal chemistry research.
The term scaffold is context- and chemist-dependant. In
chemoinformatics, ‘‘the term scaffold is mostly applied in a
rather subjective manner without adhering to clear, formal
and consistent definition’’ [25]. In most cases, the term
scaffold has been used interchangeably either as core
structure, building block, substructure, template, ring sys-
tem (RS), and/or framework. One of the most interesting
types of study of scaffolds is in the assessment of scaffold
diversity. Diversity analysis of scaffolds has been done on
Fig. 1 Benzodiazepines and
some of their numerous
biological properties
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various databases including drug data sets [4, 20, 55],
screening libraries [24, 29, 50], organic compounds dat-
abases [34, 59], and NP databases [20, 24, 27]. These studies
show that scaffold space is vast and diverse while bioactive
and drug-like compounds represent a small fraction of
principally available scaffold space [30], suggesting that
there are many scaffolds that can be systematically exploi-
ted. NPs, as a source of therapeutically useful compounds,
are biosynthesized through interaction with proteins, and
carry-forward the ‘‘embedded’’ molecular recognition
through interactions with drug targets [26, 38].
The majority (80 %) of NPs possess desirable drug-like
properties [45]. In a similar fashion, computer-based ana-
lysis revealed that NPs exhibit a remarkable structural
diversity of molecular frameworks and scaffolds with
desirable drug-like properties rendering them ideal starting
points for the design of focused libraries [20]. Approxi-
mately 40 % of the chemical scaffolds displayed in NPs are
absent from synthetic compound [31]. Making NP-like
libraries to create more complex, drug-like compounds has
the capacity to access greater chemical space [36].
Escape from Flat Scaffolds
Aromatic and heteroaromatic rings comprise a significant
proportion of compounds in ‘‘drug space,’’ however, the
developability of compounds (efficacy, pharmacokinetics,
pharmacodynamics, toxicology, and drug–drug interactions)
decreases with increasing number of aromatic rings [47].
Insertion of aromatic rings into drug-like compounds is used
to increase the potency of compounds because an aromatic
ring possesses fewer degrees of freedom than acyclic chains,
and this favorable entropy generally increases the ligand–
receptor-binding energy leading to improved potency [47].
The prevalence of aromatic and heteroaromatic rings in drug
molecules has been attributed to the synthetic ease [47].
Making compounds with aryl–aryl systems are more time
and cost effective. This is due to the fact that most of the
available synthetic methodologies and chemical substances
(both substrate and building blocks) are based on flat aro-
matic systems. Limiting the number of aromatic rings in a
drug candidate will make it more ‘‘drug-like’’ [47].
Compounds with a greater fraction of saturated carbons
(defined by Fsp3), which is an intuitive measure of com-
plexity, have a higher access rate in the drug discovery
process [36]. The Fsp3 as a simple and interpretable mea-
sure of complexity of molecules is defined as:
Fsp3 ¼ Number of sp3 hybridized carbons=Total carbon count :
More highly complex molecules, as measured by
saturation and number of chiral centers, have the capacity
to access greater chemical space [36].
Flatness Investigation of the Known Scaffolds
A flatness investigation has performed in order to classify
scaffolds that have been used in approaches involving
scaffold-hopping, privileged sub-structures, and drug RSs.
Based on some calculated mean Fsp3 value reported for
drug data sets [10, 35, 36], we defined flat and non-flat
scaffold as follows:
Flat scaffold: scaffolds with Fsp3 B 0.45.
Non-flat scaffold: scaffolds with Fsp3 [ 0.45.
Classification of Scaffold-Hopping Approaches
Sun et al. [54] recently reviewed approaches to scaffold-
hopping. By making certain changes to the original scaf-
folds such as heterocyclic replacements, ring opening or
closure, pseudopeptides, and topology-base hopping [54],
there is possibility to produce novel scaffolds. In practice,
since many of the original scaffolds came from flat mole-
cules, the final scaffolds rarely have novel 3-D orientation
of substitutions. The review classified the number of
structurally diverse scaffolds into four categories based on
the degree of novelty compared to the starting scaffold. For
example, rimonabant, a failed antiobesity drug, was
transformed by scaffold-hopping approaches to a novel
CB1 antagonist with improved pharmacological properties.
The change in the original scaffold to create the new
scaffold is classified as first degree of novelty, with a small
change of heteroatom or ring size. In this case, the
methylpyrazole core in rimonabant was replaced with a
range of five- and six-member heteroatom rings to over-
come undesirable physicochemical properties [54]. Fur-
thermore, the scaffolds that have been used more recently
(March–October 2012) in a scaffold-hopping approach
have also been examined based on their flatness feature [2,
19, 37, 61, 63–65].
Based on our defined criteria, we sorted the scaffolds as
flat and non-flat scaffolds (Fig. 2). The vast majority of
scaffolds (89 %) utilized in scaffold-hopping have incor-
porated planar frameworks (Fig. 3).
Privileged Scaffolds for Library Design and Drug
Discovery
One of the most comprehensive listings of privileged
scaffolds (PS) has published by Welsch et al. [56]. The
authors provided a list of privileged scaffolds in drug and
NPs, those found primarily in drugs, and other examples of
privileged scaffolds. The authors stated that ‘‘there is a
remarkable overlap between structures of drugs and NPs
classes as the greater number of scaffolds have members
from both groups’’. We have classified the privileged
scaffolds in the review by Stockwell et al. as flat and
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non-flat according to our previously defined Fsp3 definition
of flatness (Fig. 4). The privileged scaffolds in drug and
NPs are colored red, the PS found primarily in drugs
colored in violet and other examples of privileged scaffolds
colored in black. As demonstrated in Fig. 5, only a small
fraction (23 %) of the privileged substructures are satu-
rated non-flat scaffolds with at least one chiral centre. This
observation again implies that there has been a significant
bias toward using flat aromatic or heteroaromatic rings by
chemists according to earlier discussed reasons (ease of
synthesis and conformational restriction to increase the
potency of compounds).
Drug and Drug Candidate-Building Block Analysis
Wang and Hou [55] undertook a drug-likeness analysis in
2010. In this work, two drug data sets and one screening
data set were subjected to building block analysis. The data
Fig. 2 Flatness classification of
the scaffolds that have been
used in scaffold-hopping
approach
Fig. 3 The distribution of flat and non-flat scaffolds in scaffold-
hopping approach
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sets were approved drug data set (ADDS; FDA-approved
drugs; 1,240 entries), extended drug data set (EDDS
composed of FDA-approved drugs and experimental drugs
at different phases of clinical trials; 6,932 entries) and
screening dataset (SDS; a subset of the ‘‘clean-drug-like’’
molecules in the ZINC database). At the first step, some
clean up of the data sets was undertaken to remove small
(MW \50 Da) and large (MW [1,000 Da) molecules,
duplicated entries, and to eliminate those entries containing












































































































Fig. 4 Flatness classification of
the scaffolds that have been
used in a library of privileged
structures. (The privileged
scaffolds in drug and NPs
colored red; the PS found
primarily in drugs colored violet
and other examples of
privileged scaffolds colored
black)
Fig. 5 The distribution of flat and non-flat scaffolds in privileged
sub-structure libraries
146 Springer Science Reviews (2013) 1:141–151
123
next stage, a brute force algorithm was utilized for a
fragmentation of all molecules in the drug data sets. This
process cut every cleavable bond in silico to give frag-
ments, where a cleavable bond was defined as a single,
non-ring, non-terminal bond. A classification strategy was
then used to group the molecular fragments into three types
of building blocks, which were defined as drug scaffold
(DS), RSs, and small fragment (SF). They loosely defined
‘‘drug scaffold’’ as a ‘‘molecular fragments having at least
nine heavy atoms’’. The authors collected and individually
sorted the top 100 DSs identified from FDA-ADDS and
EDDS. We used the top 50 RSs obtained from these two
drug data sets to investigate how the RSs of drugs are
similar to each other in terms of planarity and controlling
the geometry of the molecules. We observed that 42 rings
systems were common to both data sets. In Fig. 6, we
colored the top 50 RSs identified in the ADDS in black and
those RSs in the extended drug data set but absent in the
first data set (ADDS) in blue. Figure 7 shows the distri-
bution of flat and non-flat scaffolds in the drug data sets.
Fig. 6 Flatness classification of
the RSs in Drug and drug
candidates’ data sets. The top 50
RSs identified in ADDSs
colored black and those RSs in
extended drug data set which
were absent in the ADDS
colored blue
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The proportion of non-flat RSs compared to planar RSs was
32 versus 68 %, respectively.
NP Scaffolds
Ring scaffolds embedded within all known NPs from The
DNPs (sdf version 211.9) were abstracted. All contiguous
RSs were extracted with retention of exocyclic double
bonds to terminal atoms in order to preserve important
chemical functionality. For example, to maintain the car-
bonyl oxygen present in a lactone or lactam ring.
Metal-containing RSs were excluded from consider-
ation, resulting in the identification of 18,128 RSs. An
additional MW filter (MW \350 Da) was applied to
exclude large, non drug-like RSs (e.g., polycyclic RSs
and macrocycles) resulting in 15,822 NP-derived
scaffolds.
A number of selected flat and non-flat scaffolds
embedded in NPs (abstracted from DNP) are shown in
Figs. 8 and 9 and are indicative of the fact that the majority
of NP-derived scaffolds are classified as non-flat by con-
sidering their corresponding Fsp3 values.
Fig. 7 The distribution of flat and non-flat RSs in drug and drug
candidates’ data sets
Fig. 8 Flatness classification of
the scaffolds that have been
abstracted from DNP
Fig. 9 The distribution of flat and non-flat NP scaffolds extracted
from DNP
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Conclusion
Examination of Fsp3 values calculated for each scaffold
provides further insights into the characteristics that make
naturally derived scaffolds appealing when compared to
other sources of chemical diversity. Specifically, the pre-
dominance of non-flat scaffolds embedded within NPs (i.e.,
high Fsp3) highlights a significant fundamental difference
between synthetic and naturally derived compound
screening libraries. We propose that the past and continued
future success of NPs as a source of therapeutically useful
chemical compounds may be attributed to their positioning
wholly within regions of BRCS. One characteristic of NPs
guiding this complementarity to protein-binding surfaces is
the incorporation of non-flat molecular frameworks capa-
ble of orienting peripheral functional groups in all three
dimensions.
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